Immunoglobulin fusion proteins

Details Immunoglobulin fusion proteins Immunoglobulin fusion proteins

2011-01-11

2011-01-11

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S178100, C424S192100, C435S069100, C530S387100, C536S023100

Reexamination Certificate

active

07867491

ABSTRACT:
Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

REFERENCES:
Knauf et al., “Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers,” 1988, The Journal of Biological Chemistry, vol. 263, No. 29, pp. 15064-15070.
Riott et al., “Structural Variants of the Basic Immunoglobulin Molecule,” Essential Immunology, 2001, 10th Edition, pp. 41 and 55.
Delgado et al., “The Uses and Properties of PEG-Linked Proteins,” Critical Reviews in Therapeutic Drug Carrier Systems, 1992, vol. 9, Nos. 3 and 4, pp. 249-304.
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy,” Nature, 1989, vol. 337, pp. 525-531.
Paige et al., “Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol,” Pharmaceutical Research, 1995, vol. 12, No. 12, pp. 1883-1888.
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med., 1991, vol. 173, pp. 721-730.
Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists,” The Journal of Immunology, 1993, vol. 151, No. 3, pp. 1548-1561.
Morton et al., Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2), The American Association of Immunologists, 1996, pp. 1047-1054.

Affiliated with

Also associated with

Rating

Immunoglobulin fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2710018